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ABSTRACT
Introduction: Pegylated interferon-based ther-
apy for hepatitis C virus (HCV) negatively
impacts nutritional state and patient-reported
outcomes (PROs) such as health-related quality
of life (HRQL). Clinical trials with direct-acting
antivirals (DAAs) report significant PRO
improvement but real-world data are still scarce.
Methods: Prospective cohort study recruiting
HCV patients treated with DAAs in 2015–2016.
Data at baseline, end of treatment (EOT) and
12 weeks thereafter (FU12) included: patient-re-
ported medication adherence; SF-36; Karnofsky
Performance Status; paid labour productivity;
physical exercise level; nutritional state [by
body mass index (BMI) and Jamar hand grip
strength (HGS)] and Beliefs about Medicines
Questionnaire. Potential factors predicting
these PROs were evaluated with multiple
regression analysis.
Results: A total of 68 patients were enrolled:
85% male, median age 57 years, 80% genotype
1, 40% cirrhotics, 46% haemophilia. Both cure
rate and patient-reported adherence were 97%.
SF-36 Physical Component Summary did not
change (43.2 ± 11.9, 44.9 ± 10.3 and
44.7 ± 10.9 at baseline, EOT and FU12,
p = 0.71). In contrast, SF-36 mental component
summary (MCS) decreased transiently during
therapy (49.2 ± 11.9, 44.6 ± 10.3 and
49.9 ± 12.6 at baseline, EOT and FU12,
p\0.01). Concomitant ribavirin-use was the
only independent predictor of decreased SF-36
MCS. BMI (25.7 ± 4.5 and 25.6 ± 4.4 at base-
line and EOT, p = 0.8) and Jamar HGS
(39.7 ± 13.0, 37.4 ± 11.9 and 37.9 ± 13.8 at
baseline, EOT and FU12, p = 0.56) did not
change.
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Conclusion: Our study reveals concomitant
ribavirin as the only independent predictor of
transient decrease in SF-36 mental HRQL during
DAA therapy. In contrast to interferon-based
therapy, DAAs do not affect BMI or Jamar HGS.
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INTRODUCTION
Patient-reported outcomes (PROs) have taken
centre stage in the assessment of quality provi-
sion in hepatitis C virus (HCV) care [1]. While
the main goal of HCV antiviral therapy is to
achieve a sustained virological response (SVR),
which is considered a surrogate marker for
favourable long-term hepatic and extra-hepatic
clinical outcomes [2], PROs can demonstrate
immediate change in patient’s perceived health
condition.
A wide variety of PROs such as health-related
quality of life (HRQL), labour productivity and
physical exercise level are negatively impacted
by chronic HCV infection [3–5]. Even HCV
patients with an early fibrosis stage often report
impaired HRQL, predominantly attributable to
fatigue or depression [4]. Advanced hepatic
disease such as cirrhosis is associated with fur-
ther HRQL impairment [6]. Interferon- and rib-
avirin-containing regimens also temporarily
compromise patient HRQL perception and may
lead to a detrimental nutritional state [7], poor
therapy adherence and early treatment discon-
tinuation [8]. On the other hand, HCV patients
who accomplished successful viral eradication
with an interferon-based regimen exhibited
improved HRQL following treatment compared
to non-responders [9]. The novel direct-acting
antivirals (DAAs) significantly reduce patient
treatment burden because of shorter therapy
courses and a superior side effect profile com-
pared to interferon-containing regimens. The
favourable qualities of second-generation DAAs
even resulted in PRO improvement as early as
2 weeks after treatment initiation in clinical
trials [10]. However, real-world data on PROs in
HCV patients on DAA therapy are still scarce.
The current study describes a variety of PROs in
a real-world cohort of chronic HCV patients
who received DAA treatment.
METHODS
Patient Selection and Study Design
All consecutive patients with chronic HCV who
received anti-viral treatment with an all-oral
DAA regimen at the Department of Gastroen-
terology of the University Medical Center
Utrecht in 2015–2016 were eligible for inclusion
in this observational prospective cohort study.
Patients with no comprehension of Dutch or
English languages and with either HBV or HIV
coinfection were excluded.
Patients received DAA therapy in agreement
with international guidelines [11, 12]. Medica-
tion was dispensed according to usual medical
practice and all DAAs were fully reimbursed by
the health care insurance (with the exception of
the obligatory deductible excess) [11, 12]. Fol-
low-up visits during therapy with the treating
physician were at baseline, after 2 and 4 weeks,
and thereafter at 4-week intervals. Both PROs
and routine laboratory test results were col-
lected at baseline, end of treatment (EOT) and at
12 weeks after treatment completion (FU12). It
was aimed to offer support for the patient in
cases of any marked decrease in one of the
selected PROs (e.g. severe weight loss). The
Beliefs About Medicines Questionnaire (BMQ)
[13] was collected at baseline and FU12. HCV
RNA was assessed using the Cobas Ampliprep
and Cobas TaqMan HCV test, Roche (lower
limit of detection 15 IU/mL). Sustained viro-
logical response (SVR) was defined as negative
serum HCV RNA 12 weeks post-treatment. Cir-
rhosis was defined as either
Fibroscan C 12.5 kPa) [14] or liver histology
with METAVIR classification of F4.
All procedures performed in studies involv-
ing human participants were in accordance
with the ethical standards of the institutional
(Medical Ethical Committee of the University
Medical Center Utrecht) and/or national
research committee and with the 1964 Helsinki
374 Infect Dis Ther (2018) 7:373–385
declaration and its later amendments or com-
parable ethical standards. Informed consent was
obtained from all individual participants inclu-
ded in the study.
Patient-Reported Outcomes
Health-Related Quality of Life
and Performance Status
The HRQL was assessed using a validated Dutch
version of the Short Form-36 (SF-36) [15]. This
questionnaire quantifies HRQL with scores
ranging from 0 (lowest) to 100 (highest) using
eight subscales consisting of: physical func-
tioning (PF), bodily pain (BP), role physical (RP),
general health (GH), role emotional (RE), vital-
ity (VT), social functioning (SF) and mental
health (MH). The subscales of SF-36 are sum-
marised as physical component summary (PCS)
and mental component summary (MCS). Mini-
mal clinically important difference (MCID) for
PCS and MCS was defined as a change of C 5%,
in accordance with previous literature [16].
The Karnofsky performance status (KPS)
scale, which ranges from 0 to 100, was used to
evaluate performance status [17].
Beliefs about Medicines Questionnaire
and Treatment Adherence
Patients’ attitude towards medicines was mea-
sured at baseline and FU12 using the BMQ [13],
which consists of two sections: the BMQ-gen-
eral and the BMQ-specific which are both scored
on a 5-point Likert scale. The BMQ-general
assesses beliefs about the harmfulness and
overuse of medicine in general. The BMQ-
specific assesses patients’ beliefs about the
necessity of the prescribed DAAs for controlling
their illness and their concerns about the
potential adverse consequences of taking it.
Mean scores for each subscale are computed and
higher scores indicate stronger agreement.
Additionally, the BMQ-specific is categorised
into four different groups: ‘‘accepting’’, i.e.
necessity score C 2.5 (high) and concerns
score\2.5 (low), ‘‘ambivalent’’ i.e. necessity
score C 2.5 (high) and concerns score C 2.5
(high), ‘‘indifferent’’, i.e. necessity\2.5 (low)
and concerns\ 2.5 (low), and ‘‘skeptical’’, i.e.
necessity score\2.5 (low) and concerns score
C 2.5 (high).
Patients’ self-reported medication adherence
was registered at each visit. Patient-reported
treatment adherence was expressed in percent-
ages which were calculated using the following
formula: (the number of pills taken during the
treatment period divided by the number of pills
prescribed by the physician) 9 100.
Nutritional State
Nutritional state was assessed with the volun-
tary hand grip strength (HGS) according to
Jamar. This parameter is a measure of nutri-
tional state [18] and an independent predictor
of complications in patients with cirrhosis [19].
The HGS was measured in the dominant hand
with a calibrated Jamar dynamometer (Biomet-
rics, Almere, The Netherlands) adjusted for sex,
age, and height and compared to a healthy
reference population [20–23]. The best of three
consecutive measurements was recorded (1 min
recovery time between attempts). In addition,
data on weight and body mass index (BMI) were
collected at baseline and EOT.
Paid Labour Productivity
For the assessment of paid labour productivity
(PLP) patients were asked to provide informa-
tion on their productivity status. The PLP was
defined as full time (C 36 h/week), part time
(\36 h/week) or none, and further categorised
as either white collar (physically inactive) or
blue collar (physically active) labour. Work
impairment was defined as any decrease in
working hours during or after DAA therapy.
Physical Exercise
At each study visit, patients indicated their level
of leisure physical exercise (with exclusion of
exercise during paid labour working hours).
Patients were divided into the following cate-
gories according to their physical exercise
activity per week: (1) no significant physical
exercise (\60 min of exercise); (2) 60–150 min
of low-intensity exercise; (3) > 150 min of low-
intensity exercise; (4) 60–150 min of high-in-
tensity exercise; (5)[150 min of high-intensity
exercise. Low-intensity exercise was defined as
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walking and leisure cycling. High-intensity
exercise was defined as strength training, run-
ning and intense cycling.
Statistical Analysis
Continuous data are reported as means with
standard deviations (SD) or, in cases of a non-
Gaussian distribution, as medians with
interquartile range (IQR). Discrete variables are
described as absolute and relative frequencies.
Differences between subgroups were tested for
statistical significance by independent t test or
Mann–Whitney U test, as appropriate.
Paired-samples t test or, in cases of a non-
Gaussian distribution, the Wilcoxon signed
rank test was used to analyse within-group
changes between two different time points. In
cases of three different time points, a repeated
measure ANOVA or a Friedman Test was used in
combination with post hoc analysis with Bon-
ferroni correction for multiple testing. Associa-
tions between changes from baseline of
different continuous outcomes were evaluated
with Pearson’s correlation coefficient. Univari-
able and multivariable linear regression analyses
were conducted to identify potential factors
predicting changes in KPS and SF-36 Summary
scores at EOT and FU12 compared to baseline
scores. Potential predictors that were analysed,
predominantly based on previous literature,
included: gender, age, BMI, prior treatment
exposure, use of ribavirin, presence of cirrhosis
or concomitant haemophilia [10, 24, 25]. Fac-
tors with a p value\ 0.2 in univariable analysis
were included in subsequent multivariable
analysis. Adjusted Beta coefficients with their
95% confidence intervals (CIs) were calculated.
A two-sided p value\0.05 was considered sta-
tistically significant. SPSS v.4.0 (IBM, Armonk,
NY, USA) was used for statistical analyses and
GraphPad Prism v.6.0 (GraphPad Software, La
Jolla, CA, USA) for creating graphics.
RESULTS
Patients
A total of 72 consecutive HCV patients who
received a DAA regimen were considered for
inclusion in this study. Four patients were
excluded because of language barriers. The
remaining 68 participants (Table 1) were pre-
dominantly male (85%) with a median age of
57 years. Genotypes 1a and 1b were the most
prevalent (31% and 49%, respectively) and 40%
of patients had compensated cirrhosis. Extra-
hepatic HCV manifestations such as haemato-
logic, auto-immune or dermatologic conditions
were not present in the study population.
Concomitant inherited bleeding disorders
(haemophilia A or B) were present in 46%. The
DAA regimens were sofosbuvir-based in 85%
and ombitasvir/paritaprevir/ritonavir/dasabuvir
(3D)-based in 15%. In total, 63% of all patients
received treatment with ribavirin. On average,
haemoglobin concentration declined with
1.2 mmol/L during DAA treatment and hae-
moglobin concentration had recovered com-
pletely to baseline levels at FU12. Seven patients
(10%) had a history of a depressive disorder of
which two were on long-term antidepressant
treatment. One patient stopped taking the
mood stabiliser during DAA therapy due to
resolution of symptoms. During the study per-
iod, two patients used antidepressants for rea-
sons other than depression such as attention
deficit hyperactivity disorder and neuropathic
pain. All patients completed the entire treat-
ment period with follow-up 12 weeks post-
treatment available. Adherence was 100% for 66
patients (97%). The remaining two patients
missed one and three doses, respectively, but
still achieved a SVR. Total SVR rate was 97%.
Two genotype 1b patients with mild fibrosis
(F0–F1) exhibited positive HCV RNA within
3–6 months after completion of a 3D-based
regimen. One case was classified as a relapse and
the other as a re-infection with a genotype
switch to 1a.
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Health-Related Quality of Life
and Performance Status
At baseline, the physical component summary
(PCS) was impaired in comparison with the
general Dutch population [15]; however, there
was no subsequent change in PCS during or
after DAA therapy (43.2 ± 11.9, 44.9 ± 10.3,
and 44.7 ± 10.9 at baseline, EOT and FU12,
respectively, p = 0.71) (Table 2). Patients with
an inherited bleeding disorder tended to have
lower PCS at baseline than those without an
inherited bleeding disorder (40.7 ± 10.5 vs.
45.5 ± 9.6, p = 0.06), and this discrepancy was
also observed during and after DAA treatment.
In multivariable analysis, higher BMI was found
predictive for increase of PCS score at EOT
compared to baseline (p\0.05).
The mental component summary (MCS) was
similar to the general population at baseline but
decreased transiently during therapy
(49.2 ± 11.9, 44.6 ± 10.3 and 49.9 ± 12.6 at
baseline, EOT and FU12 respectively, p\ 0.05)
(Table 2). At baseline, patients with an inherited
bleeding disorder had substantially higher MCS
score in comparison with the non-haemophilic
patients (54.7 ± 10.1 vs. 44.1 ± 11.1, p\0.05).
In contrast, cirrhotic patients had significantly
Table 1 Characteristics of chronic hepatitis C patients
and direct-acting antiviral treatments
n = 68
Age (years), median (IQR) 57 (49–64)
Male gender, n (%) 58 (85)
Ethnic descent, n (%)
Caucasian 63 (93)
North African/Middle East 4 (6)
Other 1 (1)
Baseline blood tests, median (IQR)
ALT (U/L) 74 (41–124)
Albumin (g/L) 42.2 (40.2–44.3)
Bilirubin (lmol/L) 11 (8–14)
Prothrombin time (s) 13.7 (13.2–14.4)
Thrombocytes (109/L) 182 (135–239)
Cirrhosis, n (%) 27 (40)
Child–Pugh A, n (%) 27 (100)
MELD-score, median (IQR) 7 (6–9)
Haemophilia, n (%) 31 (46)
HCV genotype, n (%)
1a 21 (31)
1b 33 (49)
2 2 (3)
3 7 (10)
4 5 (7)
Baseline HCV RNA (log 10 IU/mL),
median (IQR)
6.3 (6.0–6.5)
Peg-IFN/RBV experienced, n (%) 34 (50)
DAA treatment, n (%)
Sof/RBV 3 (4)
Sof/Sim ± RBV 12 (18)
Sof/Ldv ± RBV 17 (25)
Sof/Dac/RBV 26 (38)
3D ± RBV 10 (15)
Ribavirin, n (%) 43 (63)
Table 1 continued
n = 68
Treatment duration, n (%)
12 weeks 60 (88)
24 weeks 8 (12)
Ribavirin concentration at week 8 (mg/
L), median (IQR)
2.4 (1.7–3.4)
ALT alanine aminotransferase; BMI body mass index;
DAA direct-acting antiviral; Dac daclatasvir; HBV hep-
atitis B virus; HIV human immunodeﬁciency virus; IQR
interquartile range; Ldv ledipasvir; MELD Model for End-
Stage Liver Disease; Peg-IFB pegylated-interferon; RBV
ribavirin; Sim simeprevir; Sof sofosbuvir; 3D ombitasvir,
paritaprevir, ritonavir and dasabuvir
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lower MCS scores at baseline (45.3 ± 12.8 vs.
51.9 ± 10.6, p\0.05) than those without cir-
rhosis. In the multivariable analysis, concomi-
tant ribavirin use was the only independent
predictor of decreased MCS during therapy
(p\ 0.05) (Table 3). Although ribavirin
recipients experienced a greater decline in hae-
moglobin concentration than those treated
with ribavirin-free regimens (- 1.7 vs.
- 0.4 mmol/L, p\ 0.05), the haemoglobin
decline was not correlated with the decrease in
MSC during DAA treatment (r = 0.14, p = 0.31).
Table 2 SF36-components during DAA treatment
SF-36-components Baseline EOT FU12 p
a
Physical functioning 70.3 ± 25.0 70.7 ± 21.1 71.5 ± 26.9 0.42
Role physical 63.2 ± 37.5 49.1 ± 43.2b 69.0 ± 40.6 \0.05
Bodily pain 68.7 ± 23.3 70.9 ± 26.6 69.7 ± 24.4 0.73
General health 54.6 ± 21.4 58.5 ± 22.0 58.8 ± 21.8 0.51
Social functioning 75.7 ± 24.6 72.8 ± 24.1 79.0 ± 23.6c \0.05
Role emotional 75.6 ± 35.6 66.1 ± 42.1 75.7 ± 39.8c \0.05
Mental health 75.4 ± 17.7 68.7 ± 21.8b 76.6 ± 18.0 \0.05
Vitality 59.8 ± 21.3 54.3 ± 24.1b 65.7 ± 22.1d \0.05
Physical component summary 43.2 ± 11.9 44.9 ± 10.3 44.7 ± 10.9 0.71
Mental component summary 49.2 ± 11.9 44.6 ± 10.3b 49.9 ± 12.6 \0.05
Data presented as mean ± SD. Signiﬁcant differences in post hoc analysis (p\0.05) are reported
a The p value is reported for the repeated measures analysis (ANOVA or Friedman)
b From baseline and FU12 values
c From EOT values
d From baseline and EOT values
Table 3 Factors predicting decrease in SF-36 Mental Component Summary at end of DAA treatment compared to baseline
Univariable analysis Multivariable analysis
Beta-coefﬁcient CI p Beta-coefﬁcient CI p
Age - 0.07 - 0.37 to ? 0.23 0.64
Female gender 8.99 ? 1.09 to ? 16.89 0.03 7.17 - 0.46 to ? 14.80 0.07
BMI - 0.50 - 1.16 to ? 0.17 0.14 0.00 - 0.64 to ? 0.64 1.0
Treatment experienced - 4.53 - 10.48 to ? 1.42 0.13 - 2.65 - 8.42 to ? 3.12 0.36
Cirrhosis - 1.65 - 7.91 to ? 4.61 0.60
Hemophilia - 1.98 - 8.05 to ? 4.09 0.52
Ribavirin therapy 2 6.03 2 12.03 to 2 0.04 0.05 2 7.74 2 13.73 to 2 1.75 0.01
Uni- and multivariable analysis of predicting factors and SF-36 Mental Component Summary scores at end of treatment
with reference to baseline values. Signiﬁcant values (p\0.05) in bold
CI conﬁdence interval
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Patients not receiving ribavirin had stable MCS
levels during treatment (53.2 ± 10.8,
50.3 ± 11.0 and 52.9 ± 11.2 at baseline, EOT
and FU12 respectively, p = 0.28).
The eight SF-36 subscales generally decreased
during treatment with improvement 12 weeks
after end of therapy (Fig. 1). The SF-36 vitality
scale, (considered the most affected component
of SF-36 in HCV patients[16]), was the only
subscale that demonstrated significant
improvement at FU12 compared to baseline
(? 5.9, CI 1.2–10.0, p\0.05).
The overall Karnofsky performance status
(KPS) score at baseline was high (92.3 ± 11.7)
although patients with cirrhosis had a consid-
erable lower KPS level than non-cirrhotics
(87.0 ± 13.8 vs. 96.1 ± 7.7, p\0.05). Similar to
the SF-36 MCS score, KPS showed a significant
transient decrease during treatment with sub-
sequent recovery (92.3 ± 11.7, 84.2 ± 13.7 and
90.3 ± 11.8 at baseline, EOT and FU12 respec-
tively, p\ 0.05). No predictive factors were
identified for decline in KPS during treatment in
multiple regression analysis.
Beliefs About Medicines
Paired BMQ results at baseline and 3 months
after end of therapy were available for 49
patients (72%). According to the BMQ-specific
questionnaire, 37% of all patients had an ‘ac-
cepting’ attitude towards DAA therapy which
increased to 55% at FU12 (Table 4). This can be
explained by a decrease in the proportion of
patients with ‘high concerns’ about the poten-
tial adverse consequences of taking DAAs from
56% at baseline to 25% at EOT. Overall, changes
in attitude towards DAA at FU12 compared to
baseline did not reach significance (p = 0.10).
When considering beliefs about medication in
general, treatment with DAAs had no signifi-
cant impact on the beliefs about harmfulness
(2.3 ± 0.7 and 2.3 ± 0.6 at baseline and FU12,
p = 0.65) and overuse (2.5 ± 0.6 and 2.6 ± 0.8
at baseline and FU12, p = 0.51).
Nutritional State
Baseline BMI indicated normal weight (BMI
18.5–25 kg/m2), overweight (BMI[ 25–30 kg/
m2) and obesity (BMI[30 kg/m2) in 44%, 40%
and 16% of patients, respectively. Overall, no
substantial BMI change was observed during
therapy (25.7 ± 4.5 and 25.6 ± 4.4 at baseline
and EOT, respectively, p = 0.78) and severe
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Fig. 1 Changes of SF-36 components during and
12 weeks after direct-acting antiviral therapy compared
to baseline. Mean change in SF-36 component scores
during and after treatment compared to baseline values.
EOT end of treatment, FU12 12 weeks after end of
treatment. *p\ 0.05 in the repeated measures analysis
(ANOVA or Friedman) with post hoc analyses
Table 4 Attitude of patients with chronic hepatitis C
infection towards direct-acting antiviral therapy
Baseline FU12
a
Accepting 18 (37) 27 (56)
Ambivalent 19 (39) 10 (20)
Indifferent 3 (6) 10 (20)
Skeptical 9 (18) 2 (4)
Attitude towards DAA therapy assessed with the BMQ-
speciﬁc. Results are given for patients with complete
evaluation at two time-points (n = 49). FU12, 12 weeks
after follow-up. Data presented as counts with relative
frequencies
a Overall difference at FU12 compared to baseline was
non-signiﬁcant (p = 0.1) (Wilcoxon signed rank test)
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weight loss (i.e. C 10% of basal values) did not
occur.
In 36 patients, hand grip strength (HGS)
measurements according to Jamar were avail-
able at baseline, EOT and/or FU12. At baseline,
HGS was sufficient in 52–88% of the group,
depending on reference values that were used,
and this ranged between 40% and 78% at both
EOT and at FU12 [21, 23]. Mean HGS during
antiviral therapy did not change (39.7 ± 13.0,
37.4 ± 11.9 and 37.9 ± 13.8 at baseline, EOT
and FU12 respectively, p = 0.56). A total of 5
patients experienced a reduction of greater than
10% in HGS at EOT; however, this returned to
baseline levels for all but one patient at FU12
(Fig. 2).
Paid Labour Productivity and Physical
Exercise
Data on paid labour productivity, physical
exercise and performance status are given in
Table 5. At baseline, paid labour was performed
by 50% (54% full time white collar, 6% full time
blue collar, 32% part-time white collar and 8%
part-time blue collar).
After therapy completion, complete loss of
labour and work impairment were reported by
8% and 19% of all patients with paid labour at
baseline, respectively. All three patients with
complete loss of labour had an inherited
bleeding disorder. At FU12, two of these three
had returned to working the same hours as
before treatment initiation.
Prior to antiviral therapy, 32% of all patients
performed no significant leisure physical exer-
cise at all, and this proportion increased there-
after (52% and 59% at EOT and FU12,
respectively). Before initiation of therapy, those
HCV patients who performed exercise mostly
trained at low intensity (76%) and a smaller
proportion performed high-intensity exercise
(24%). Abandonment of all significant physical
exercise during DAA treatment occurred in 48%
of those patients who exercised before DAA
therapy. At FU12, exercise was reinitiated by
22% of these patients. There was no difference
in haemoglobin concentration decline during
treatment in patients who had stopped exer-
cising compared to those who continued (- 1.3
vs. - 1.0 mmol/L, p = 0.40). Overall, the level of
physical exercise during DAA treatment chan-
ged significantly (p\0.05).
DISCUSSION
In addition to efficacy and safety data, PROs are
important in quantifying the impact and value
of DAA therapy [26, 27]. Although clinical trial
data suggest that PRO improvement in HCV
patients can be accomplished even shortly after
DAA treatment initiation [10], this has yet to be
confirmed by real-world evidence.
The main finding of our study was that
HRQL remained stable during and after DAA
treatment when considering the PCS. Several
previous clinical DAA trials demonstrate signif-
icant improvement of PCS at EOT and/or FU12
[28–30]. However, a temporary on-treatment
decline in PCS during sofosbuvir/ribavirin
treatment has also been reported [24]. Differ-
ences between our current study and previous
Fig. 2 Hand grip strength according to Jamar before
direct-acting antiviral therapy, at end of treatment and at
12 weeks follow-up. Bars indicate means. Black circles with
connecting lines indicate individual patients. EOT end of
treatment, FU12 12 weeks after end of treatment
380 Infect Dis Ther (2018) 7:373–385
trials could be related to a different patient
selection. For instance, a large proportion of our
patients had an inherited bleeding disorder and
this subgroup exhibited lower PCS scores
throughout the treatment and follow-up period
compared to those without an inherited bleed-
ing disorder. The mental component summary
(MCS) revealed an important on-treatment
decline in our patients with complete recovery
at follow-up. Concomitant ribavirin was the
only independent predictor of the temporary
decline in MCS. Previous literature reports sim-
ilar and reversible on-treatment declines in the
MCS in HCV patients treated with a ribavirin-
containing regimen. Of note, those patients
who did not receive ribavirin in these clinical
trials showed an early increase in the MCS after
the start of DAA treatment [28, 31]. Patients in
our study with a ribavirin-free regimen had no
significant change in MCS level during therapy
compared to baseline. With respect to the
individual SF-36 domains, vitality demon-
strated the most pronounced and clinically
important improvement at FU12 compared to
baseline (? 5.9), which is in accordance with
previous literature that describes vitality as one
of the key SF-36 domains affected by HCV [16].
Patients with an inherited bleeding disorder
comprise a large proportion of our cohort with
excellent SVR-rates of 97%, which is in agree-
ment with other studies in this patient category
[32, 33]. To our knowledge, this is the first real-
world report on PROs of HCV patients with an
inherited bleeding disorder during DAA treat-
ment. Patients with an inherited bleeding dis-
order had substantially lower PCS scores in
comparison with the other patients. This could
relate to the consequences of haemophilia (e.g.
disabling arthropathy). In contrast, their MCS
scores at each time-point during the study per-
iod were significantly higher than in the other
patients. MCS scores in patients with haemo-
philia have previously been described to be
relatively high in comparison with the country-
specific normative scores [34, 35]. Since quality
of life measurement expresses the patient’s
subjective perception of their level of func-
tioning compared to what they believe to be
optimal, we hypothesise that the relatively high
MSC scores in haemophiliacs in our study
Table 5 Paid labour productivity and physical exercise during and after direct-acting antiviral therapy
Baseline EOT FU12 p
a
Paid labour productivity, n (%) b 0.12
None 34 (50) 35 (51) 28 (48)
White collar 29 (43) 26 (38) 23 (39)
Blue collar 5 (7) 7 (9) 8 (14)
Paid labour productivity h/week, median (IQR)c 36 (26–40) 36 (19–40) 40 (24–40) 0.63
Physical exercise, n (%) d 0.01
None 22 (32) 35 (52) 36 (59)
Low intensity, 60–150 min 17 (25) 10 (15) 11 (18)
Low intensity, 150–240 min 18 (27) 11 (16) 7 (11)
High intensity, 60–150 min 2 (3) 7 (10) 4 (7)
High intensity, 150–240 9 (13) 5 (7) 3 (5)
EOT end of treatment, FU12 12 weeks after follow-up, IQR interquartile range
a p value for overall changes during treatment (Friedman test)
b Data on paid labour productivity at FU12 was available for 59 patients
c Data depicted for those with paid labour at baseline, EOT or FU12
d Data on physical exercise at FU12 was available for 61 patients
Infect Dis Ther (2018) 7:373–385 381
reflect a high degree of chronic disease accep-
tance in this well-adapted patient group.
It has been reported that patients’ beliefs
about medicines as assessed with the BMQ is
related to medication adherence in inflamma-
tory bowel disease and depressive disorders
[36, 37]. In this cohort, the selection of patients
with an ‘accepting’ attitude towards DAAs
improved from 37% at baseline to 55% at FU12.
This was mainly due to a decrease in ‘high con-
cerns’ about the potential adverse consequences
of taking DAAs from 56% at baseline to 25%. At
FU12, 76% of patients scored ‘high’ on beliefs
about DAA necessity and 75% scored ‘low’ on
concerns about DAAs, so both domains would
have to be addressed equally to improve the
overall patient acceptance of DAAs in the future.
The relationship between patients’ attitude and
adherence could not be investigated since 97%
of this cohort reported perfect adherence
(= 100%). This may be an overestimation of true
adherence since adherence in this study was
patient-reported and therefore subject to recall
bias. Nevertheless, non-adherence does not
appear a major problem in DAA therapy [38, 39].
Malnutrition can predict complications in
patients with cirrhosis [19, 22] and severe
weight loss ([ 10%) during treatment often
occurred in the interferon era [7]. To our
knowledge, our study is the first report on
nutritional state of HCV patients during all-
DAA treatment. In our cohort, no significant
changes in mean BMI and hand grip strength
according to Jamar were found.
Infection with HCV imposes an economic
burden with impaired work productivity
[3, 40, 41]. Our study shows a high unemploy-
ment rate of 50% in patients with chronic HCV
at baseline, which is in line with large interna-
tional health surveys (7–74%) [3, 42, 43] and a
previous study in the Netherlands (54%) [44].
Work impairment (i.e. decrease in working
hours) in our cohort occurred in 15% during
treatment which is lower than previously
described (26–30%) [5, 42, 43]. However, actual
work impairment may be higher as patients
only reported on absenteeism and not presen-
teeism (i.e. being on the job but with dimin-
ished work productivity because of illness)
which has been documented to be the
predominant factor in work impairment in
HCV patients receiving interferon-based ther-
apy [5, 42, 43]. About one-third (32%) of all
HCV patients performed no leisure physical
exercise at baseline, comparable with previous
literature (32–52%) [3, 43].
Our study has several strengths and limita-
tions. First of all, it provides results on a wide
range of validated PRO measures that were col-
lected prospectively. Secondly, it contributes to
the scarce knowledge on PROs in HCV patients
with an inherited bleeding disorder. On the
other hand, the inclusion of patients with an
inherited bleeding disorder might cause some-
what diminished generalisability of the results.
Of further note, patients with decompensated
cirrhosis were not included in this study.
Although we made efforts to minimise the
amount of loss to follow-up, there are still some
missing values in a number of outcomes vari-
ables which may have influenced our results.
Finally, the relatively small number of patients
may have prohibited us from demonstrating
overall improvement in PROs and also pre-
cluded analysis of the potential effects of dif-
ferent DAA regimens on PRO values.
CONCLUSION
In conclusion, our real-world experience with
DAAs reveals reversible decline of the SF-36
Mental Component Summary without change
in the Physical Component Summary or the
nutritional state. Concomitant ribavirin ther-
apy was the only predictive factor for decreased
Mental Component Summary.
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